Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

2 recruiting

Enrollment Performance

Analytics

Phase 1
1(33.3%)
Phase 3
1(33.3%)
N/A
1(33.3%)
3Total
Phase 1(1)
Phase 3(1)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT07202728Recruiting

A Multi-center Cohort Study of Hydatidiform Mole in China (CN-HM-01)

Role: collaborator

NCT06941766Phase 1Recruiting

Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors

Role: collaborator

NCT05811676Phase 3Completed

Tranexamic Acid for the Prevention of Postpartum Hemorrhage in Pregnant Women With Placenta Previa

Role: collaborator

NCT05152446Not ApplicableTerminated

Implementation of an Infusion Management Scheme to Improve Patient Outcome in Tertiary Children's Hospitals

Role: collaborator

All 4 trials loaded